<DOC>
	<DOCNO>NCT00104624</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well docetaxel work treat old woman metastatic breast cancer whether help improve ability perform daily activity .</brief_summary>
	<brief_title>Docetaxel Treating Older Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine degree autonomy instrumental activity daily live on-therapy 6 12 month , measure Lawton 's Instrumental Activities Daily Living Scale , old woman metastatic adenocarcinoma breast treat docetaxel . Secondary - Determine response rate patient treat drug . - Determine overall progression-free survival patient treated drug . - Determine degree autonomy daily activity measure Katz 's Activities Daily Living Scale , patient treat drug . - Determine mood status , measure Geriatric Depression Scale , patient treat drug . - Determine toxicity drug patient . OUTLINE : This multicenter study . Patients receive docetaxel IV day 1 15 . Treatment repeat every 28 day 6 course . Ability perform daily activity assess periodically . PROJECTED ACCRUAL : A total 53 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma breast Metastatic disease Measurable disease CT scan MRI Requires firstline chemotherapy metastatic disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 70 Sex Female Menopausal status Not specify Performance status Meets follow criterion : Lawton 's Instrumental Activities Daily Living score ≥ 4 Katz 's Activities Daily Living score ≥ 4 Life expectancy More 3 month Hematopoietic Hemoglobin &gt; 10 g/dL Neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic ALT AST &lt; 1.5 time normal Bilirubin normal Alkaline phosphatase &lt; 2.5 time normal Renal Creatinine clearance &gt; 30 mL/min Cardiovascular No congestive heart failure No unstable angina pectoris No myocardial infarction within past year No uncontrolled hypertension No highrisk uncontrolled arrhythmias Other Geriatric Depression Score &lt; 12 No active uncontrolled infection No active peptic ulcer No uncontrolled diabetes mellitus No inflammatory bowel disease No history hypersensitivity docetaxel drug formulate polysorbate 80 No history significant neurologic psychiatric disorder , include psychotic disorder , dementia , seizure , would preclude give informed consent No familial , social , geographical , psychological condition would preclude study followup No definite contraindication corticosteroids No serious illness medical condition No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy No prior concurrent trastuzumab ( Herceptin^® ) Chemotherapy Prior neoadjuvant adjuvant chemotherapy breast cancer allow More 2 year since prior docetaxel paclitaxel No concurrent chemotherapy Endocrine therapy No 1 prior hormonal therapy regimen metastatic disease At least 10 day since prior hormonal therapy No concurrent hormonal therapy No concurrent chronic corticosteroid Concurrent lowdose corticosteroid ( ≤ 20 mg/day methylprednisolone equivalent ) allow provide treatment initiate &gt; 6 month study entry Radiotherapy Not specify Surgery Not specify Other More 30 day since prior active treatment another clinical trial Concurrent bisphosphonates allow bone metastasis , osteoporosis , osteopenia No concurrent anticancer therapy No concurrent investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>